A Double Blind, Placebo-controlled, Randomised, Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GMC-252 in Healthy Male Subjects and Male Type 2 Diabetics
Phase of Trial: Phase I
Latest Information Update: 06 Jun 2017
At a glance
- Drugs GMC 252 (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- Sponsors Genmedica Therapeutics
- 07 Jun 2017 Biomarkers information updated
- 30 May 2017 Planned End Date changed from 1 Sep 2017 to 1 Dec 2017.
- 30 May 2017 Planned primary completion date changed from 1 Jun 2017 to 1 Sep 2017.